News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
ES-SCLC 5-year survival outcomes inIMpower133 and IMbrella study
Photo taken from meduniwien.ac.at
Aug 14, 2024, 07:04

ES-SCLC 5-year survival outcomes inIMpower133 and IMbrella study

Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X, about recent paper published in Lung Cancer Journal:

“ES-SCLC (Extensive Stage Small Cell Lung Cancer)

  • 5-year survival outcomes inIMpower133 and
    IMbrella a extension study.
  • 5-year OS rate 12% “

Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella a extension study

Authors: Martin Reck, Rafal Dziadziuszko, Shunichi Sugawara, Steven Kao, Maximilian Hochmair, Florian Huemer, Gilberto de Castro, Libor Havel, Reyes Bernabé Caro, György Losonczy, Jong-Seok Lee, Dariusz M. Kowalski, Zoran Andric, Raffaele Califano, Andrea Veatch, Gregory Gerstner, Marta Batus, Stefanie Morris, Monika Kaul, Vaikunth Cuchelkar, Huafei Li, Bradford J. Danner, Barzin Y. Nabet and Stephen V. Liu

ES-SCLC 5-year survival outcomes inIMpower133 and IMbrella study

Source: Katsuaki Maehara/X

Andrea Veatch Barzin Y. Nabet Bradford J. Danner cancer cell lung cancer Dariusz M. Kowalski Florian Huemer Gilberto de Castro Gregory Gerstner György Losonczy Huafei Li IMbrella inIMpower133 Jong-Seok Lee Katsuaki Maehara Libor Havel Lung Cancer Journal Marta Batus Martin Reck Maximilian Hochmair Medical Education Colleagues Monika Kaul OncoDaily Oncology Rafal Dziadziuszko Raffaele Califano Reyes Bernabé Caro SCLC Shunichi Sugawara Stefanie Morris Stephen V Liu Steven Kao Vaikunth Cuchelkar Zoran Andric
Special Coverage
Insight
Dec 24, 2024, 18:19
ICR’s spinout company “Sentinal4D” has officially been launched
Blog
Dec 24, 2024, 18:16
Ronit Satchi-Fainaro: Target Therapies in P-selectin-expressing cancers
Blog
Dec 24, 2024, 18:11
Bishal Gyawali: Are U.S. patients paying twice for cancer drugs?
Blog
Dec 24, 2024, 18:09
Megan-Claire Chase: Navigating cancer as a single person diagnosed under 40
Blog
Dec 24, 2024, 18:06
Elvina Almuradova: ESPAC4 Long-Term Results in Journal of Clinical Oncology
Blog
Dec 24, 2024, 18:03
Andrea Lancia: Excited to participate in the next GU Oncology Early Career Thought Leaders Conference!
Blog
Dec 24, 2024, 17:55
Layth Mula-Hussain: Prognostic factors and survival in patients with NSCLC and brain metastases
Career
Dec 24, 2024, 17:45
Narjust Florez and Scott Armstrong Received the 2025 Health Innovators Award for EQUAL Study at Dana-Farber Brigham Cancer Center
Blog
Dec 24, 2024, 17:41
Mahipal Singh Bhanot: From Fear to Faith - Fortis Gurugram’s Legacy in Hematology
Blog
Dec 24, 2024, 17:39
Arif Kamal: Food is Medicine in Oncology Care Symposium
Blog
Dec 24, 2024, 17:32
Three-Year Overall Survival with Nivolumab + Relatlimab rela-nivo in Advanced Melanoma
Blog
Dec 24, 2024, 17:29
VCU Massey Comprehensive Cancer Center - Current obstacles in achieving equitable care for patients with cancer